Research | Open | Published:
Liquid biopsy in mice bearing colorectal carcinoma xenografts: gateways regulating the levels of circulating tumor DNA (ctDNA) and miRNA (ctmiRNA)
Journal of Experimental & Clinical Cancer Researchvolume 37, Article number: 124 (2018)
Circulating tumor DNA (ctDNA) and miRNA (ctmiRNA) are promising biomarkers for early tumor diagnosis, prognosis and monitoring, and to predict therapeutic response. However, a clear understanding of the fine control on their circulating levels is still lacking.
Three human colorectal carcinoma cell lines were grown in culture and as tumor xenograft models in nude mice. Chip-based and droplet digital PCR platforms were used to systematically and quantitatively assess the levels of DNAs and miRNAs released into the culture supernatants and mouse blood plasma.
Strikingly, mutated DNAs from the same (KRAS) and different (PIK3CA and FBWX7) genomic loci were differentially detected in culture supernatants and blood, with LS174T releasing 25 to 60 times less DNA in culture, but giving rise to 7 to 8 times more DNA in blood than LoVo cells. Greater LS174T ctDNA accumulation occurred in spite of similar CD31 immunostaining (micro-vascularization) and lesser proliferation and tissue necrosis as compared to LoVo. As to the three selected miRNAs (miR-221, miR-222 and miR-141), all of them were constitutively present in the plasma of tumor-free mice. Micro-RNA miR-141 was released into HT-29 cell supernatants 10 and 6.5 times less abundantly with respect to LoVo and LS174T, respectively; on the contrary, release of miR-141 in blood of HT-29 xenografted mice was found similar to that observed in LoVo and LS174T mice.
Taken together, our results support the existence of multiple, finely tuned (non-housekeeping) control gateways that selectively regulate the release/accumulation of distinct ctDNA and miRNA species in culture and tumor xenograft models. Different xenografts (proxies of different patients) considerably differ in gateway usage, adding several layers of complexity to the well-known idea of molecular heterogeneity. We predict that even high tissue representation of mutated DNA and miRNA may result in insufficient diagnostic analyte representation in blood. In this respect, our data show that careful modeling in mice may considerably help to alleviate complexity, for instance by pre-screening for the most abundant circulating analytes in enlarged sets of tumor xenografts.
Soluble biomarkers in body fluids, particularly those circulating in the bloodstream, provide key diagnostic information in several human diseases, including cancer. The carcinoembryonic antigen (CEA), for instance, has been used for decades to diagnose and monitor cancer progression, since elevated levels are associated with cancer spreading. However, as for many other ‘first generation’ biomarkers, circulating levels of this analyte are variable in healthy individuals and often overlap in unaffected and diseased populations, detracting from their general applicability [1,2,3].
In the last few years, the introduction of precision diagnostics has revolutionized the entire biomarker field. Unlike conventional markers, ‘precision’ biomarkers such as circulating tumor DNA (ctDNA) and miRNA (ctmiRNA) reveal genetic and epigenetic aberrations that directly drive cancer . In addition, unique mutations of ctDNAs are virtually cancer-specific, and ctmiRNA signatures pinpoint specific biological features. Indeed, every cancer patient is believed to host a unique set of tumor aberrations (e.g. DNA mutations and/or overexpressed miRNAs), each of which can be detected in the blood and used as a surrogate or ‘index’ biomarker for cancer diagnosis, prognosis, therapeutic assignment, and follow-up .
Detection of ctDNA/ctmiRNAs in body fluids, usually referred to as liquid biopsy, has demonstrated great potential. However, this approach also suffers from some limitations, both theoretical and technical [5, 6]. Extreme personalization may be challenging. The biological processes underpinning release of index aberrations are complex, highly dependent on the analyte being considered, and may differ in different patients. RAS mutations, for instance, are often subclonal, preventing their consistent appreciation in a liquid biopsy format . Therefore, capturing the mutational complexity of cancer by liquid biopsy will require the combination of multiple index aberration, ideally from different classes of analytes, into a single multi-marker assay.
In light of this, it is mandatory to address the variables determining the availability of circulating analytes and design optimized multi-marker panels, but this may prove extremely challenging and ethically questionable if one exclusively relies on human specimens. Additionally, in vitro spiking experiments with known amounts of DNAs/miRNAs may fail to resolve the mechanisms of analyte formation, release in the extracellular spaces, export into the bloodstream, and eventually persistence in a soluble, detectable form. Therefore, controlled animal models are required to optimize liquid biopsy approaches, and spare ethically sensitive clinical material from cancer patients.
In this study, we take advantage of chip-based and droplet digital PCR platforms and enumerate ctDNAs and miRNAs released from three human colorectal carcinoma (CRC) cell lines with different KRAS genotypes. We systematically compare levels of mutations from the same (KRAS) and different (PIK3CA and FBWX7) genomic loci and miRNAs (namely miR-221, miR-222, and miR-141) in cell extracts and culture supernatants on the one hand, and the corresponding mouse tumor xenografts and matched blood samples from these mice on the other. This simple and informative experimental model reveals the existence of crucial gateways that are likely to determine biological fates and clinical usefulness of single ctDNA and ctmiRNA species in individual patients.
Cell lines and supernatants
Human CRC cells (HT-29, LoVo and LS174T) were purchased from the American Type Culture Collection (ATCC). HT-29 cells were derived from a KRAS-WT, differentiated colorectal adenocarcinoma. LoVo cells (originally described as Dukes’ type C, grade IV) and LS174T cells (Dukes’ type B) harbor a heterozygous KRAS c.38G > A mutation (G13D) and a heterozygous KRAS c.35G > A mutation (G12D), respectively. Somatic mutations and their Variant Allelic Frequencies (VAFs) were confirmed by interrogating the Cancer Cell Line Encyclopedia ( https://portals.broadinstitute.org/ccle ). Cell identity was confirmed by HLA genotyping, as described . Cells were grown in RPMI 1640, 10% fetal bovine serum, 1% l-glutamine and 1% penicillin/streptomycin (all from Euroclone, Milan, Italy) in a humidified atmosphere containing 5% CO2. To permit the accumulation of DNA and miRNAs in culture supernatants, cells were grown for 72 h to 70% confluency and manually counted by the Trypan Blue exclusion method. Cells were harvested and either pelleted and snap-frozen (for miRNA extraction, see below), or Formalin Fixed and Paraffin Embedded (FFPE), as routinely done for histological specimens (for DNA extraction, see below). Spent medium was then collected, spun twice at 4 °C (2000×g for 20 min and 16,000×g for 10 min), and immediately stored at − 80 °C in aliquots.
Tumor xenografts and plasma preparation
Animal studies were performed according to Directive 2010/63/EU and Italian Decree Law 26/2014. They were approved by the EU Research Executive Agency (REA), the Intramural Regina Elena Board for Animal Welfare, and the Italian Ministry of Health (prot n. 700–2015-PR, dated July 17th, 2015). Tumor xenotransplants were established by inoculating 3 × 106 cells from the HT-29, LS174T and LoVo cell lines in the flank of 4-month old Nu/CD1 mice (Charles River Laboratories, Italy). Xenotransplants were allowed to grow to two different sizes (300 and 1000 mm3, 6 mice per group for each of the three cell lines). Additional independent experiments were carried out on smaller cohorts of mice and individual animals. Tumors were taken at sacrifice along with blood, and were divided into two fragments: one half was snap-frozen in liquid nitrogen, the other half was FFPE-processed exactly as routinely done for human diagnostic histopathology. Frozen tissues were used as the source of miRNAs, FFPE samples were used as the source of genomic DNA, for morphological evaluation (hematoxylin/eosin stain), and for immunohistochemistry (see Additional file 1). Blood was collected in 6 mL BD Vacutainer K2E tubes (BD, #368857) and centrifuged within 1 h at 2,000×g for 20 min at 4 °C. Plasma was recovered and further centrifuged at 16,000×g for 10 min at 4 °C to remove cell debris, and stored at − 80 °C until extraction.
DNA was obtained according to the manufacturer’s (Qiagen, Hilden, Germany) instructions from four different sources. Genomic DNA was extracted by the QIAamp® DNA FFPE Tissue Kit from FFPE inclusion slices of either (a) cell pellets of cultured cells or (b) tumor xenotransplants. ctDNA was extracted with the QIAamp® CNA kit from either (c) 2 mL of culture supernatants or from (d) 2 mL of mouse plasma. DNAs from (c) and (d) were eluted in a final volume of 30 μL, and stored at − 20 °C. All DNAs were quantified with the Qubit dsDNA assay kit (LifeTechnologies, Carlsbad, CA, USA) prior to dPCR analysis.
RNA was extracted from frozen cell (5 × 105) pellets by the TRI-Reagent (Sigma-Aldrich, St.Louis, MO, USA) and from cell culture supernatants according to Turchinovich et al.  with minor modifications. Briefly, 400 μL of culture supernatants were lysed in 1.2 ml of TRIzol LS (Thermo Fisher Scientific, Waltham, MA, USA) in the presence of 12 μg of carrier glycogen (Thermo Fisher Scientific) and 400 attomoles of C. elegans miR-39-3p (cel-miR-39-3p) (Thermo Fisher Scientific) to control miRNA recovery efficiency. Following phase-partitioning by nuclease-free chloroform (Sigma-Aldrich), miRNAs were purified using miRNeasy Serum/Plasma columns (Qiagen). RNA was eluted in 18 μL of nuclease-free water (Sigma-Aldrich). The snap-frozen tumor fragment was homogenized using an IKA T10 Basic Ultraturrax (IKA Werke, Staufen, DE) in TRI-Reagent at maximum speed for 1 min and then processed as above. For the analysis of ctmiRNA, blood plasma (150 μL) was treated to disrupt exosomes and denaturate miRNA-binding proteins in 5 volumes of QIAzol Lysis Reagent (Qiagen). After the addition of 400 amoles of cel-miR-39-3p, total RNA was purified with the miRNeasy Serum/Plasma Kit (Qiagen) in a final volume of 18 μL. All RNAs were stored at − 80 °C until use.
Digital PCR on genomic DNA, supernatants, mouse tissues and ctDNA
DNA samples were dispensed in the chip-based QuantStudio™ 3D Digital PCR System (Thermo Fisher Scientific), and amplified using selected TaqMan™ SNP Genotyping Assays for human KRAS mutations (Table 1). dPCR reactions were set up in a final volume of 15 μL, containing 7.5 μL of 2× QuantStudio™ 3D Digital PCR Master Mix, 0.75 μL of TaqMan® SNP Genotyping assays (Life Technologies), and different DNA templates, each adjusted in 6.75 μL water, as follows. Genomic DNAs from cells and tumor tissues were 50 ng; DNAs from culture supernatants were 6.75 μL equivalent to 450 μl of supernatant; ctDNAs were 6.75 μL equivalent to 45 μl plasma. Thermal cycling was as follows: 10 min at 96.0 °C, 39 cycles at 56.0 °C for 2 min, 30 s at 98.0 °C, and a final elongation step of 2 min at 60 °C. Copy numbers were calculated assuming that a human haploid genome DNA corresponds to 3.3 pg DNA.
Reverse transcription droplet digital PCR (RT-ddPCR) assays for microRNA expression analysis
Levels of miR-141, miR-221 and miR-222 were assessed by Reverse Transcription droplet digital PCR (RT-ddPCR). 300 ng of total RNA (from cells and tissues) or 3 μL of purified miRNAs (corresponding to 65 μL of supernatants and 25 μL of plasma) were reverse transcribed using the TaqMan™ miRNA Reverse Transcription Kit (Thermo Fisher Scientific) according to the manufacturer’s manual, in a final reaction volume of 20 μl. 1.3 μL of cDNA, undiluted (for supernatants and plasma) or diluted 1:100 (for cells and tissues), was amplified in a final volume of 20 μL, in the presence of ddPCR Supermix for Probes (no dUTP) 2X (Bio-Rad) and TaqMan™ miRNA 20X assays (Thermo Fisher Scientific) (Table 1). 40 μL of droplets emulsion was automatically generated using Automated Droplet Generator (AutoDG) (Bio-Rad) and amplified in a thermal cycler. The following thermal cycler conditions were used: 95 °C for 10 min, 40 cycles of 95 °C for 15 s and 60 °C for 1 min and a final step of 98 °C for 10 min. Droplets were analyzed using the QX200 Droplet Reader, and data analysis was performed with QuantaSoft version 1.7.4 (Bio-Rad).
Study workflow: cells and tumor xenografts as models for liquid biopsy
To assess ctDNAs and miRNAs, a model study was designed that includes cells, culture supernatants, tumor xenografts, and blood samples, as outlined in Fig. 1. Three different CRC cell lines (HT-29, LoVo and LS174T) were selected as proxies of clinically evident cancers and sources of soluble analytes. Because RAS mutations are assessed in the routine diagnosis of colorectal carcinoma to assign epidermal growth factor receptor (EGFR) blockade therapy , we selected cells that are either wild-type for KRAS (HT-29), or carry the G12D and G13D mutations (LS174T and LoVo, respectively). DNAs and miRNAs were extracted from both cells and culture supernatants, as outlined in Fig. 1 (left). The same cells were also modeled as xenotransplants in nude mice (Fig. 1, right). Matched tumor tissue and blood samples were taken at sacrifice. All biological specimens were then subjected to dPCR, ddPCR and RT-qPCR analysis as outlined in Materials and Methods.
Genomic and ctDNAs in cells, supernatants, xenotransplants and mouse blood
DNAs were obtained from: (1) cell pellets of HT-29, LS174T and LoVo cells grown in culture flasks to approximately (±5%) the same numbers; (2) equal amounts of supernatants from the above flasks; (3) genomic DNAs from tumor xenotransplants grown to 300 mm3 (±15%) in size (all tumors); and (4) equal amounts of pooled blood plasma obtained from the above animals (n = 6). DNAs and ctDNAs were subjected to dPCR for KRAS G12D and G13D, and for control PIK3CA H1047R and FBXW7 R505C mutations, to test DNA fragments originating from the same (KRAS) as well as distinct (PIK3CA and FBXW7) genomic loci in two different (LS174T and LoVo) CRC cell lines. Mutated RAS sequences were detected in LoVo and LS174T (Fig. 2, panels I-X), but not in KRAS-WT HT-29 cells (E-H), as expected. VAFs in cells and tissues were approximately 50% in all cases (I, M, K, O, U, V), as expected, with the exception of KRAS in LoVo (Q and S, approximately 75%), confirming copy number variation of the KRAS MUT allele in the absence of chromosome 12 duplication (see whole genome sequencing data in the Cancer Cell Line Encyclopedia at https://portals.broadinstitute.org/ccle ). However, and interestingly, when free soluble DNAs were considered, a strikingly higher variability was readily observed in both VAFs and absolute copy numbers per mL. Specifically, KRAS G12D DNA from LS174T was almost 60 times less abundant than G13D DNA from LoVo (958 vs 56,359 copies/mL; compare J and R) in culture supernatants and, viceversa, it was approximately 8 times more abundant (compare L and T; 139 vs 17 c/mL) in blood, demonstrating a 500-fold difference in the ability of the two cell lines to generate accumulation of RAS ctDNA in cell supernatants vs blood of tumor-xenotransplanted mice. Likewise, comparison of PI3KCA and FBXW7 (compare N to V, and P to X) demonstrated greater (25 times) and lesser (7 times) relative abundances of the two mutations in culture supernatants and blood, resulting in a 175-fold difference that is in full agreement with KRAS ctDNA blood accumulation preferences (LS174T > LoVo). Altogether, ctDNA levels appear to reflect a cell line-dependent property only marginally affected by the genomic regions of origin of the soluble analytes. Preferential ctDNA accumulation in the blood of LS174T xenografts was reproduced in: (a) two separate cohorts of 6 mice carrying larger (1000 mm3) tumors, (b) two additional, distinct plasma samples obtained by pooling blood from two cohorts of three animals each, and (c) two plasma samples from two individual animals (data not shown). Altogether, our results suggest the existence of a minimum of two gateways. The first gateway predominantly operates in LS174T cells by controlling DNA scavenging towards the microenvironment, since this cell line releases in vitro much less DNA than LoVo. Conversely, the latter gateway becomes evident in LoVo cells when they are grown as tumor xenografts, and prevents the accumulation of mutated ctDNA in blood.
Cellular and histopathological features potentially associated with ctDNA accumulation
At least 3 major cellular/histopathological features are known to account for DNA accumulation in the extracellular milieu and/or in blood: cell proliferation, tissue necrosis and tumor micro-vasculature . A simple explanation of ctDNA accumulation based on cell proliferation is unlikely, since LS174T proliferate much faster than LoVo cells both in culture and as xenografts (doubling times of 24 h vs 96 h in culture, and 4 days vs 17 days in the mouse, respectively), but the preferential accumulation of LS174T DNA is evident only in blood. It may then be hypothesized that this preferential ctDNA release might depend on the tissue architecture, e.g. necrosis or micro-vasculature. However, morphological evaluation revealed higher percentages of necrotic areas in low-ctDNA-releasing LoVo as compared to LS174T xenografts (30% vs 45%). Moreover, staining with antibodies to the endothelial marker CD31 demonstrated very similar numbers (about 14/microscopic field) of blood micro-vessels in LS174T and LoVo xenografts (Additional file 1: Figures S1 and S2). These results suggest that ctDNA gateways operate independently of tissue architecture, e.g. they are likely dependent on constraints on ctDNA release that operate both at single-cell and whole-body levels, but independent from housekeeping functions associated with cell proliferation, tumor necrosis and tumor vascularization.
miRNAs in cell lines and culture supernatants
Next, we wondered whether similar gateways regulate circulating miRNAs. Three miRNAs (miR-221, miR-222 and miR-141) were selected since they were previously described to affect colorectal cancer biology and clinical behavior [11, 12]. RNAs from dry frozen pellets and the corresponding culture supernatants were reverse transcribed, and amplified by ddPCR. 2D plots of representative miR-222-3p experiments and the complete dataset for the three miRNAs (cell lines and supernatants) are shown in Fig. 3a (top and bottom panels respectively). In parallel, in Fig. 3b, are reported the copy number/μl of RNA of all the three miRs analized in cells and supernatants (dots and diamonds respectively). From Fig. 3 it may be seen that miR-222 is more abundant in the supernatants from the cells in which it is expressed most (for instance 5.454 and 7.383 miR-222 molecules/μl of RNA are present in the supernatant of LoVo and HT-29 cells, respectively; similarly, the intracellular accumulation of miR-222 was 9.016 and 3.326 molecules/μl of RNA). Data reported in Fig. 3b indicate that miR-221 and miR-222, that belong to the same miRNA cluster, are proportionately expressed in cells and supernatants, whereas miR-141 levels do not correlate between cells and supernatants, since HT-29 cells express high levels of miR-141 (1.066 molecules/μl of RNA, compared the lower 6.045 amounts of LoVo cells) but do not efficiently release it into the medium (8.122 molecules/μl of RNA, compared the higher 4.963 amounts of LoVo supernatants). Additional ddPCR results are displayed in Additional file 1: Figure S3 and were confirmed by RT-qPCR (Additional file 1: Figure S4), although this latter technique systematically overestimated miRNA concentrations. To exclude that bovine miRNAs (that are contained in FBS and are highly homologous to human miRNAs) might contribute significant noise to PCR assays aimed at tumor miRNAs, we reverse transcribed from complete culture medium and from medium conditioned by cells grown in culture to 70% confluency. As shown in Additional file 1: Figure S5, the contribution of bovine miRNA was negligible. Altogether, these results rule out trivial technical artifacts and demonstrate a specific gateway preventing miR-141 release into HT-29 supernatants. When the results shown in Fig. 3 are taken together with those shown in Fig. 2, it can be concluded that, similar to ctDNAs, miR-141 was released into HT-29 cell supernatants 10 and 6.5 times less abundantly with respect to LoVo and LS147T cells, respectively; on the contrary, release of miR-141 in blood of HT-29 xenografted mice was found similar to that observed in the blood of LoVo and LS147T xenografted mice.
miRNAs in tumor tissues and plasma from xenografted mice
Next, we analyzed tumor xenotransplants and their corresponding plasma specimens using the same approach (Fig. 4). A representative example of miR-222 content is shown in Fig. 4a and all the quantitative data for miR-141, miR-221 and miR-222 are given in Fig. 4b. This resulted in a graphical outline very similar to that of Fig. 3. Comparison of the two figures (representative 2D ddPCR plots and the complete dataset from all xenotransplants in the top and bottom panels, respectively) demonstrates at glance that miR-141, poorly released in the culture supernatant (Fig. 3), is instead clearly detectable in plasma (Fig. 4) as the other microRNA analyzed, i.e. miR-221 and miR-222. Also in this case, miRNA levels were independently assessed by RT-qPCR, that confirmed ddPCR results (Additional file 1: Figures S6 and S7). Finally, we investigated whether cross-species miRNA homology might influence our in vivo results. To this end, we quantitated baseline, endogenous miR-221, miR-222 and miR-141 levels in tumor-free, healthy nude mice. Both RT-ddPCR and RT-qPCR demonstrated that circulating miRNAs were detectable even in the absence of tumor growth (Fig. 5). Thus, whereas bovine miRNAs do not contribute significant background in vitro (see above), mouse miRNAs do, and this affects the interpretation of the in vivo results. The differences between tumor-bearing and tumor-free mice were clearly appreciable for all the three miRNAs analyzed on HT-29 xenografts. In particular, it should be underlined that, miR-141 was significantly more abundant in the plasma of mice bearing HT-29 tumor xenografts as compared to their tumor-free littermates. This result is compatible with the hypothesis suggesting that tumor masses induce systemic miR-141 accumulation in spite of the intrinsic poor ability of HT-29 cells grown in vitro to release this miRNA in the culture supernatant.
Both circulating tumor DNAs and miRNAs are being increasingly applied as early diagnostic, prognostic and companion biomarkers of target therapy, particularly in a liquid biopsy setting . Liquid biopsy is a powerful tool applicable to all or most human cancers, including colorectal, lung, melanoma, and breast neoplasms, to cite a few, but a detailed knowledge of the molecular mechanisms underlying the release of circulating analytes is still lacking.
Experimental modeling by tumor xenografts has been proposed to characterize the rules of ctDNA [13,14,15,16] and miRNA [17,18,19,20] release into the bloodstream. In all these studies, ctDNAs and miRNAs were shown to be released into the bloodstream following upstream, ‘default’ or ‘housekeeping’ cellular events. ctDNAs accumulated as a result of apoptotic and non-apoptotic pathways involving DNA fragmentation and DNA packaging with shuttle proteins. miRNAs accumulated as a result of their conventional biogenesis in subcellular vesicles. The above studies demonstrated that analytes release can be successfully modeled in the mouse.
In this report, we wondered whether a substantial analyte fraction might be lost before ctDNAs and miRNAs hit the bloodstream, or in the bloodstream itself, e.g. whether analyte release is finely tuned downstream of default biogenesis. Interestingly, we found that non-housekeeping, cell line-specific ‘gateways’ operate on specific analytes, and may have opposite influences on a given analyte in vitro and in vivo. For instance, we found that DNAs, regardless as to whether they are from the same (KRAS mutations at codons 12/13) or different (PIK3CA and FBXW7 mutations) genomic regions, are all more efficiently released from LoVo than LS174T cells, whereas the reverse occurs when these tumor cells are grown as xenotransplants, e.g. LS174T ctDNAs are much more abundant in blood. Cell line-specific preferences are estimated, depending on the specific DNA, to range from 175 to 500-fold, and do not appear to depend on ‘housekeeping’ factors such as cell proliferation, growth of tumor xenografts, necrosis, or microvasculature density. This implies a minimum of two separate, finely tuned, gateways/checkpoint: (a) the first gateway blocks ctDNA release from cells and is particularly efficient in LS174T; (b) the second gateway is distinct, prevents steady-state accumulation in blood, presumably operates in both xenotransplants, but it is more evident in LoVo. These gateways act at the cell and whole-body levels, respectively, but their precise nature will require further investigation.
Essentially the same concept applies to miRNAs. As to the least abundant (in our set) miR-141, it was released by all tested cell lines much less efficiently than miR-221 or miR-222, and this was particularly evident in HT-29 cells (see the quantitative values of Fig. 3 and Fig. 4). By contrast, miR-141 was clearly detectable in the bloodstream of HT-29 xenotransplanted mice. At first sight, one might interpret these results as a gateway removal in vivo. However, murine miR-141 (identical to its human orthologue) is abundant in tumor-free mice. Thus, from the present data it is impossible to determine whether the cellular release gateway opens up in vivo (e.g. HT-29 cells start releasing miR-141 when grown as tumor xenografts) or miR-141 accumulates as a result of a xenograft-mediated systemic effect (e.g. ctmiR-141 is contributed by normal mouse cells as a result of tumor implantation). Thus, whereas RAS mutations can be specifically detected in tumor-bearing mice with no interference of endogenous WT RAS murine sequences (Fig. 2), circulating endogenous murine miRNAs indistinguishable from their human counterparts are present in tumor-free mice and may be a confounding factor when interpreting results.
Regardless, our data demonstrate that gateways on the one hand, and/or host systemic effects induced by the tumor on the other, influence the presence of ctDNAs and miRNAs and can be identified. Thus, careful modeling in mice may considerably help (with caveats) in selecting optimal biomarkers for clinical use as well as validate anti-miRNA therapeutic approaches [21,22,23].
From a more general viewpoint, tumor-xenotransplanted mice and other in vivo models may have an important role because they resolve biological variables from technical variables (such as handling and storage of biological fluids, pre-analytical processing, as well as DNA and RNA isolation protocols) that might affect efficient marker detection by liquid biopsy [24,25,26,27,28]. Finally, tumor-bearing mice may be useful to compare different analytical strategies including, among others, different PCR/RT-PCR and NGS platforms, instruments and protocols, as well as PCR-free methods .
Although the number of ctDNAs and miRNAs taken into account in the present study is limited, our data clearly show in a strictly controlled setting that different cell lines give rise to very different liquid biopsy ctDNA and miRNA profiles. Assimilating each of the three tested cell lines/xenografts to a distinct tumor growing in a different patient, it is tempting to speculate that multiple, finely tuned (non-housekeeping) control gateways exist that selectively regulate the release/accumulation of distinct ctDNA and miRNA species. Tumors from different patients may then considerably differ in gateway usage, adding several layers of complexity to the well-known idea of molecular heterogeneity. For instance, a mutated DNA or miRNA highly represented in the tumor may not be proportionately represented in the blood of a given patient. Analyte under-representation will make it more difficult than expected to interrogate the clinical variety of colorectal tumors. On this basis, it is predicted that very large panels of index aberration are necessary, and that future, careful modeling in mice may considerably help to identify the analytes most affected by individual gateways. Enlarged sets of cell line xenografts and, preferably, patient-derived xenografts are necessary to this end.
Circulating tumor DNA
Circulating tumor microRNA
Epidermal growth factor receptor
Formalin fixed and paraffin embedded
Polymerase chain reaction
Reverse transcription- droplet digital PCR
Reverse transcription quantitative PCR
Variant Allelic Frequency
Zhong W, Yu Z, Zhan J, Yu T, Lin Y, Xia ZS, et al. Association of serum levels of CEA, CA199, CA125, CYFRA21-1 and CA72-4 and disease characteristics in colorectal cancer. Pathol Oncol Res. 2015;21(1):83–95. https://doi.org/10.1007/s12253-014-9791-9.
Grunnet M, Sorensen JB. Carcinoembryonic antigen (CEA) as tumor marker in lung cancer. Lung Cancer. 2012;76(2):138–43. https://doi.org/10.1007/s12253-014-9791-9.
Shao Y, Sun X, He Y, Liu C, Liu H. Elevated levels of serum tumor markers CEA and CA15-3 are prognostic parameters for different molecular subtypes of breast Cancer. PLoS One. 2015;10(7):e0133830. https://doi.org/10.1371/journal.pone.0133830.
Siravegna G, Marsoni S, Siena S, Bardelli A. Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol. 2017;14(9):531–48. https://doi.org/10.1038/nrclinonc.2017.14.
Page K, Guttery DS, Zahra N, Primrose L, Elshaw SR, Pringle JH, et al. Influence of plasma processing on recovery and analysis of circulating nucleic acids. PLoS One. 2013;8(10):e77963. https://doi.org/10.1371/journal.pone.0077963.
Spindler KL, Appelt AL, Pallisgaard N, Andersen RF, Brandslund I, Jakobsen A. Cell-free DNA in healthy individuals, noncancerous disease and strong prognostic value in colorectal cancer. Int J Cancer. 2014;135(12):2984–91. https://doi.org/10.1002/ijc.28946.
Rachiglio AM, Esposito Abate R, Sacco A, Pasquale R, Fenizia F, Lambiase M, et al. Limits and potential of targeted sequencing analysis of liquid biopsy in patients with lung and colon carcinoma. Oncotarget. 2016;7(41):66595–605. https://doi.org/10.18632/oncotarget.10704.
Giacomini P, Giorda E, Pera C, Ferrara GB. An ID card for tumour cell lines: HLA typing can help. Lancet Oncol. 2001;2:658–8. https://doi.org/10.1016/S1470-2045(01)00554-X.
Turchinovich A, Weiz L, Langheinz A, Burwinkel B. Characterization of extracellular circulating microRNA. Nucleic Acids Res. 2011;39(16):7223–33. https://doi.org/10.1093/nar/gkr254.
Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 2012;486(7404):532–6. https://doi.org/10.1038/nature11156.
Cai K, Shen F, Cui JH, Yu Y, Pan HQ. Expression of miR-221 in colon cancer correlates with prognosis. Int J Clin Exp Med. 2015;8(2):2794–8.
Qin J, Luo M. MicroRNA-221 promotes colorectal cancer cell invasion and metastasis by targeting RECK. FEBS Lett. 2014;588(1):99–104. https://doi.org/10.1016/j.febslet.2013.11.014.
Garcia-Olmo DC, Gutierrez-Gonzalez L, Ruiz-Piqueras R, Picazo MG, Garcia-Olmo D. Detection of circulating tumor cells and of tumor DNA in plasma during tumor progression in rats. Cancer Lett. 2005;217(1):115–23. https://doi.org/10.1016/j.canlet.2004.06.043.
Rago C, Huso DL, Diehl F, Karim B, Liu G, Papadopoulos N, et al. Serial assessment of human tumor burdens in mice by the analysis of circulating DNA. Cancer Res. 2007;67(19):9364–70. https://doi.org/10.1158/0008-5472.CAN-07-0605.
Thierry AR, Mouliere F, Gongora C, Ollier J, Robert B, Ychou M, et al. Origin and quantification of circulating DNA in mice with human colorectal cancer xenografts. Nucleic Acids Res. 2010;38(18):6159–75. https://doi.org/10.1093/nar/gkq421.
Bronkhorst AJ, Wentzel JF, Aucamp J, van Dyk E, du Plessis L, Pretorius PJ. Characterization of the cell-free DNA released by cultured cancer cells. Biochim Biophys Acta. 2016;1863(1):157–65. https://doi.org/10.1016/j.bbamcr.2015.10.022.
Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008;105(30):10513–8. https://doi.org/10.1073/pnas.0804549105.
Selth LA, Townley S, Gillis JL, Ochnik AM, Murti K, Macfarlane RJ, et al. Discovery of circulating microRNAs associated with human prostate cancer using a mouse model of disease. Int J Cancer. 2012;131(3):652–61. https://doi.org/10.1002/ijc.26405.
Waters PS, McDermott AM, Wall D, Heneghan HM, Miller N, Newell J, et al. Relationship between circulating and tissue microRNAs in a murine model of breast cancer. PLoS One. 2012;7(11):e50459. https://doi.org/10.1371/journal.pone.0050459.
Greystoke A, Ayub M, Rothwell DG, Morris D, Burt D, Hodgkinson CL, et al. Development of a circulating miRNA assay to monitor tumor burden: from mouse to man. Mol Oncol. 2016;10(2):282–91. https://doi.org/10.1016/j.molonc.2015.10.004.
Broderick JA, Zamore PD. MicroRNA therapeutics. Gene Ther. 2011;18(12):1104–10. https://doi.org/10.1038/gt.2011.50.
Brognara E, Fabbri E, Bazzoli E, Montagner G, Ghimenton C, Eccher A, et al. Uptake by human glioma cell lines and biological effects of a peptide-nucleic acids targeting miR-221. J Neuro-Oncol. 2014;118(1):19–28. https://doi.org/10.1007/s11060-014-1405-6.
Christopher AF, Kaur RP, Kaur G, Kaur A, Gupta V, Bansal P. MicroRNA therapeutics: discovering novel targets and developing specific therapy. Perspect Clin Res. 2016;7(2):68–74. https://doi.org/10.4103/2229-3485.179431.
Bronkhorst AJ, Aucamp J, Pretorius PJ. Adjustments to the preanalytical phase of quantitative cell-free DNA analysis. Data Brief. 2016;6:326–9. https://doi.org/10.1016/j.dib.2015.12.009.
Sherwood JL, Corcoran C, Brown H, Sharpe AD, Musilova M, Kohlmann A. Optimised pre-analytical methods improve KRAS mutation detection in circulating tumour DNA (ctDNA) from patients with non-small cell lung Cancer (NSCLC). PLoS One. 2016;11(2):e0150197. https://doi.org/10.1371/journal.pone.0150197.
Pallisgaard N, Spindler KL, Andersen RF, Brandslund I, Jakobsen A. Controls to validate plasma samples for cell free DNA quantification. Clin Chim Acta. 2015;446:141–6. https://doi.org/10.1016/j.cca.2015.04.015.
Brunet-Vega A, Pericay C, Quilez ME, Ramirez-Lazaro MJ, Calvet X, Lario S. Variability in microRNA recovery from plasma: comparison of five commercial kits. Anal Biochem. 2015;488:28–35. https://doi.org/10.1016/j.ab.2015.07.018.
Ma M, Zhu H, Zhang C, Sun X, Gao X, Chen G. "Liquid biopsy"-ctDNA detection with great potential and challenges. Ann Transl Med. 2015;3(16):235. https://doi.org/10.3978/j.issn.2305-5839.2015.09.29.
Giuffrida MC, Zanoli LM, D'Agata R, Finotti A, Gambari R, Spoto G. Isothermal circular-strand-displacement polymerization of DNA and microRNA in digital microfluidic devices. Anal Bioanal Chem. 2015;407(6):1533–43. https://doi.org/10.1007/s00216-014-8405-4.
The authors are grateful to Drs. Rocco Fraioli and Adele Petricca for excellent technical and secretarial help, respectively.
This work was supported by the European Union (EU) Horizon 2020 Research and Innovation Programme (GA #633937, project ULTRAsensitive PLAsmonic devices for early CAncer Diagnosis (ULTRAPLACAD), and by Associazione Italiana per la Ricerca sul Cancro (AIRC) (IG #13575 to RG, IG# 14204 and IG #19052 to PG). MA is the recipient of a three-year AIRC fellowship (id. 19503).
Availability of data and materials
All data generated or analysed during this study are included in this published article (and its supplementary information files).
Ethics approval and consent to participate
Animal studies were performed according to Directive 2010/63/EU and Italian Decree Law 26/2014, and approved by the EU Research Executive Agency (REA), the Intramural Regina Elena Board for Animal Welfare, and the Italian Ministry of Health (prot n. 700–2015-PR, dated July 17th, 2015).
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary analysis. (DOCX 4152 kb)